FDA Approves Muscle Drug, the MA Gold Rush Ending, with Stuart Blitz & Scott Law | HCN EP. 7
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
This week on HCN: the FDA approves ISEMBYLD, a myostatin-targeting muscle drug for SMA — is this the next GLP-1 story? Employer health costs keep climbing while 91% of premium growth still tracks care spending. The Medicare Advantage gold rush faces tighter CMS rules. Oura opens the books ahead of an IPO, Apple pushes to become your health home, and we ask whether menopause supplements actually work after 25 years of thin evidence.
Special guests: Stuart Blitz, cofounder and COO of Hone…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.